Marker Therapeutics Inc
MRKR
Company Profile
Business description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Contact
2450 Holcombe Boulevard
Suite e BCM-A, MS: BCM251
HoustonTX77021
USAT: +1 713 400-6400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
stocks
For US software stocks, it’s been an AI bust, not a boom
Once-hot software names are lagging. Are they good buys?
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.20 | 19.20 | -0.22% |
| CAC 40 | 8,017.26 | 57.59 | 0.72% |
| DAX 40 | 23,411.83 | 172.65 | 0.74% |
| Dow JONES (US) | 46,569.81 | 121.54 | 0.26% |
| FTSE 100 | 9,582.99 | 48.08 | 0.50% |
| HKSE | 25,894.55 | 178.05 | 0.69% |
| NASDAQ | 22,776.41 | 95.59 | -0.42% |
| Nikkei 225 | 48,659.52 | 33.64 | 0.07% |
| NZX 50 Index | 13,480.43 | 19.42 | -0.14% |
| S&P 500 | 6,696.61 | 8.51 | -0.13% |
| S&P/ASX 200 | 8,537.00 | 26.70 | -0.31% |
| SSE Composite Index | 3,870.02 | 33.26 | 0.87% |